BOSTON, Mass. — Ironwood Pharmaceuticals Inc. said it will present new data and analyses across its gastrointestinal and rare disease programs at Digestive Disease Week 2026, scheduled for May 2–5 in Chicago.
The company said findings from its LANDMARK survey will highlight healthcare professional perspectives on the burden of total parenteral nutrition for patients with short bowel syndrome, including insights into treatment challenges and priorities for therapies that could reduce dependence on intravenous nutrition and hydration.
Short bowel syndrome is a chronic condition marked by reduced ability to absorb nutrients and fluids, often requiring long-term parenteral support to sustain life. Patients with intestinal failure frequently face significant treatment burden, reduced quality of life, and increased risk of complications such as infection. Ironwood estimates about 18,000 adults in the United States, Europe, and Japan live with the condition and rely on parenteral support.
“Short bowel syndrome remains a complex and underserved condition where patients and clinicians face significant challenges, particularly for those who rely on parenteral support, which is often life-sustaining but can be associated with substantial treatment burden,” said Michael Shetzline, M.D., Ph.D., chief medical officer, senior vice president and head of research and drug development at Ironwood Pharmaceuticals. “By bringing forward real-world healthcare professional perspectives, we aim to deepen understanding of current management and the factors that shape SBS-IF care in everyday practice and help inform future therapeutic approaches.”
Ironwood is advancing apraglutide, an investigational long-acting GLP-2 analog, for patients with short bowel syndrome who depend on parenteral support. The company said it will also present long-term safety and tolerability data from the STARS clinical trial program evaluating the therapy in adults with the condition.
Additional presentations will focus on linaclotide, including data from a Phase 3 open-label safety extension study in pediatric patients ages 2 to 5 with functional constipation, as well as post hoc analyses in adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.
The company said the data will include analyses examining the impact of pH-modifying agents on linaclotide’s efficacy and safety, as well as outcomes across patient subgroups defined by race, ethnicity, and age, and pooled results from multiple Phase 3 studies in severe chronic idiopathic constipation.
Presentations will be delivered by researchers and clinicians from institutions including Augusta University, Nationwide Children’s Hospital, Weill Cornell Medical College, the Cleveland Clinic, and Rigshospitalet in Copenhagen.
